Go to Top
INVENTOR LOGIN

Details

Project TitleRepurposing Non-Antibiotic Drugs for Tuberculosis Treatment Through Host Modulation
Track Code2016-092
Short Description

A novel method for the treatment of tuberculosis, especially pyrazinamide resistant disease.

Abstract

The present invention also allows for discovery of new TB drugs acting on such targets.

 
Tagstuberculosis, tuberculosis treatment, tb
 
Posted DateApr 28, 2017 5:15 PM

Researcher

Name
Graham Timmins
Ke Jian Liu
Xixi Zhou

Manager

Name
Jovan Heusser

Background

Pyrazinamide (PZA) is a significant anti-tuberculosis drug, with its powerful sterilizing activity, in fighting tuberculosis, a disease caused by Mycobacterium tuberculosis. When activated into pyrazinoic acid by the bacterial enzyme pyrazinamidase, a specific and important macrophage enzyme is inhibited, which contributes to pyrazinamide’s antimycobacterial activity and prevention of macrophage necrosis.  This enzyme is also the target of several drugs, so that the host-modulating effects of pyrazinamide can be obtained with these compounds, and this is independent of pyrazinamide drug resistance.

Technology Description

Researchers at the University of New Mexico have developed a novel method for the treatment of tuberculosis, especially pyrazinamide resistant disease. The present invention also allows for discovery of new TB drugs acting on such targets.

Advantages/Applications

  • Enables treatment of pyrazinamide resistant disease
  • Maximize effects of combination drug regimens in treating tuberculosis and MDR-TB
  • Resolves a host-directed target of pyrazinamide activity

INQUIRES

STC has filed intellectual property on this exciting new technology and is currently exploring commercialization options. If you are interested in information about this or other technologies, please contact Arlene Mirabal at amirabal@stc.unm.edu or 505-272-7886.